Tag:

Abbott

Latest Headlines

Latest Headlines

Abbott med tech revenues up slightly as company prepares for sale of its generics unit

Abbott's medical device revenue was $1.37 billion in the second quarter, an increase of 1.2% year over year. Meanwhile, the diagnostics division reported quarter sales of $1.19 billion, a 4.8% increase, the company revealed July 16.

Abbott CEO: 'I don't feel the pressure to invert'

Wall Street analysts took advantage of a conference call on Abbott's just-announced sale of its developed market generics business to ask about some of their favorite topics, future M&A and the recent onset of  tax inversion mania among life science companies. 

Abbott continues evolution toward devices, planning to sell generics portfolio for $5.3B

Following the $5.3 billion sale of Abbott Laboratories' developed market generic drugs business to Mylan, diagnostics and devices will account for the majority of the company's sales, while pharmaceuticals' contribution to company-wide sales will stand at about 15%, based on 2013 earnings.  

Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business

Mylan has been hunting for a buy. Now, it's found one. The Pittsburgh-based generics specialist is buying a big chunk of Abbott Laboratories' drug business, in a stock swap worth $5.3 billion. With $2 billion in annual sales, the products would jack up Mylan's top line by almost 30%.

Abbott gets EU go-ahead for implant in aging eyes

Cataracts are big business for Abbott. It's ready to roll out the latest in its line of implantable Tecnis lenses in Europe after recently receiving a CE Mark for the product, which will be used to treat cataract patients who may also have a diminished ability, due to aging, to focus on near objects (presbyopia).

Abbott bulks up in Russia with $495M deal for Veropharm

Abbott Laboratories has said it plans to focus its branded generics business on a select group of rapidly expanding emerging markets. It appears Russia is one of them. The Illinois-based drugmaker will shell out up to $495 million to buy the fast-growing Russian generics maker VeroPharm from local billionaire Roman Avdeev.

Profits crashing for some med tech giants

Qmed  has put together the five biggest drops in profit for medtech companies in 2014, and it's not looking good for device giants so far this year.

Out with the old, in with the new: Merck, GSK, others put established drugs on the block

Some of pharma's biggest players have already said they're looking into jettisoning their portfolios of older meds or selling off certain established products with an eye toward newer, fast-growing drugs. And as that trend takes flight, other pharma companies may look to make similar moves, The Wall Street Journal 's sources say.

Abbott expands manufacturing in Latin America with CFR deal

Abbott gets a portfolio of 1,000 new drugs and expects to see its sales in the Latin American market double with its $3 billion buyout out of Chile's CFR Pharmaceutical.

CMS closer to coverage for Abbott's MitraClip

Abbott may not have to look too far for a big win after the Centers for Medicare & Medicaid Services proposed coverage for its only FDA-approved device for transcatheter mitral valve repair or replacement.